drugset / Trial / NCT00967538

Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments

NCT00967538

Phase 4 Completed 89 enrolled Innovaderm Research Inc. Amgen · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate safety and efficacy of etanercept in patients with psoriasis who had an unsatisfactory response to adalimumab and infliximab.

Timeline

Start
2009-09
Primary completion
2014-07
Completion
2014-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg

Indications